Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction

Cardiology

Volumn 90, Issue 1, 1998, Pages 37-42

  Serebruany, Victor L ^a,b   Bahr, Raymond D ^a   O'Connor, Christopher M ^a   Lowry, David R ^a   Gurbel, Paul A ^a  

^a St Agnes and Union Mem Hospitals   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Acute myocardial infarction; Aspirin; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CD31 ANTIGEN; PADGEM PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART PROTECTION; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ANTIGENS, CD31; ASPIRIN; BLOOD PLATELETS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, CELL SURFACE; THROMBOLYTIC THERAPY;

EID: 0031872813     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006814     Document Type: Article

References (35)

1. Winther K, Husted SE, Vissinger H: Low dose acetylsalicyclic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction). Pharmacol Toxicol 1994;74:141-147.
2. Prentice CR: Antithrombotic therapy in the secondary prevention of myocardial infarction. Am J Cardiol 1993;72:G175-G180.
3. Eccleston D, Topol EJ: Inhibitors of platelet IIb/IIIa as augmenters of thrombolysis. Coron Artery Dis 1995;6:947-955.
4. Davies MJ, Thomas AC, Knapman PA, Hangarter JR: Intramyocardial platelet aggregation in patients with acute myocardial infarction suffering sudden ischemic cardiac death. Circulation 1986;73:418-427.
5. Gurbel PA, Serebruany VL, Bahr RD, Shustov AR, Ohman EM: Effects of alteplase and reteplase on platelet aggregation and major surface antigen receptor expression during the first 24 hours in patients with acute myocardial infarction. The GUSTO-III platelet study. Circulation 1997;96:I-261.
6. Boger RH, Bode-Boger SM, Gutzki FM, Tsikas D. Weskott HP, Frolich JC: Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. Clin Sci (Colch) 1993;84: 517-524.
7. Mehta JL: Emerging options in the management of myocardial ischemia. Am J Cardiol 1994;73:A18-A27.
8. Gurbel PA, Serebruany VL, Komjathy SF, Collins ME, Sane DC, Scott HJ, Schlossberg ML, Herzog WR: Regional and systemic platelet function is altered by myocardial ischemiareperfusion. J Thromb Thrombolysis 1995;1: 187-194.
9. Golino P, Ashton JH, Glass-Greenwalt P, McNatt J, Buja LM, Willerson JT: Mediation of reocclusion by thromboxane with tissue type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988;77: 678-684.
10. Serebruany VL, Bahr RD, Shustov AR, Carpo C, Gurbel PA: Marked heterogeneity of platelet aggregation and surface receptor expression in patients presenting with acute myocardial infarction. Circulation 1997;96:I-261.
11. Serebruany VL, Gurbel PA, Shustov AR, Dale-sandro M, Gumbs SI, Grabletz BS, Bahr RD, Ohman EM, Topol EJ: Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute myocardial infarction. Stroke 1998;29:235-238.
12. The GUSTO III Investigators: A comparison of reteplase and alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
13. Ruggeri ZM: New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-235.
14. Ault KA: Flow cytometric measurement of platelet function and reticulated platelets. Ann NY Acad Sci 1993;677:293-308.
15. Serebruany VL, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, Folkers K, Gurbel PA: Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol 1997;29:16-22.
16. The RISK Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830.
17. Langford EJ, Wainwright RJ, Martin JF: Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vase Biol 1996; 16:51-55.
18. Prager NA, Torr-Brown SR, Sobel BE, Adendschein DR: Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993;22:296-301.
19. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A: Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997;29:1515-1519.
20. Chronos NA, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH: Aspirin does not affect the flow cytometric detection of fibrinogen binding to or release of alpha-granules or lysosomes from human platelets. Clin Sci (Colch) 1994;87:575-580.
21. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-386.
22. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR: Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993;82:505-512.
23. Frandsen NJ, Winther K, Pedersen F, Christiansen I, McNair P: Time course of platelet α-granule release in acute myocardial infarction treated with streptokinase. Heart 1996;75: 141-144.
24. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW: Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease? J Am Coll Cardiol 1996;28:343-353.
25. Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J: Downregulation of human platelet reactivity by neutrophils: Participation of lipoxygenase derivatives and adhesive proteins. J Clin Invest 1993;92:1357-1365.
26. Rand ML, Perry DW, Packham MA, Gemmell CH, Yeo EL, Kinlough-Rathbone RL: Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurement of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 1996;52:288-294.
27. Montalescot G: Use of aspirin in coronary disease. Presse Méd 1995;24:925-927.
28. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: Theory and practice. Blood 1994; 83:885-898.
29. Serebruany VL, Herzog WR, Gurbel PA, Schlossberg ML, Scott HJ, Vogel VA: NPC 15669, an anti-inflammatory leucine derivate, reduces in vitro platelet aggregability in both swine and human plasma. J Thromb Thrombolysis 1995;1:171-178.
30. Mustard JF, Packham MA: Factors influencing platelet function: Adhesion, release and aggregation. Pharmacol Rev 1970;22:97-102.
31. Weiss HJ, Aledort LM, Kochwa S: The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968;47:2169-2173.
32. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT: Flow cytometry reveals activated GP IIb-IIIa complex on plateles from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 1995;6:395-410.
33. Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH: Does thrombolytic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Circulation 1996;93:792-729.
34. Makkar RR, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, Shah PK, Jordan RE, Kaul S: Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 1997;95:1015-1021.
35. Thomas GR, Thibodeaux H, Errett CJ, Bednar MM, Gross CE, Bennett WF: Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis. Stroke 1995;26:1039-1046.